The FDA recently approved the imaging drug Cytalux which will help surgeons better locate ovarian cancer. Learn more: advancedovariancancer.net/?p=1329
#ovariancancer #tealwarriors #gyncsm #ovariancancer survivor
'Break through the Darkness' #litbrain #TumorGlow I was so happy to see my patient who was featured advertising campaign years ago. On the wall is photo of her dancing with daughter! Congratulations Dr Singhal FDA approval Cytalux lung cancer! #braintumor Penn Neurosurgery Penn Medicine MD
Updated phase III data of Cytalux (OTL38) dye detecting micro disease in ovarian cancer debulking from Dr. Tanyi and Robert Wenham Moffitt Cancer Center with 86% sensitivity and 28% false + rate at high volume centers optimizing surgical resection!! #SGOMtg #gyncsm MoffittGYNONC
FDA approved new 'glowing tumor' imaging drug, Cytalux,'which is attracted to ovarian cancer tissue & illuminates it when exposed to fluorescent light, allowing surgeons to more easily find & more precisely remove the cancer.' Penn Medicine - Abramson Cancer Center On Target Laboratories, Inc. pennmedicine.org/news/news-rele… 1/n
🚨🔥Hot off the press: U.S. FDA approves #ImagingDrug #Pafolacianine ( #Cytalux ) to assist #Surgeons in identifying #LungCancer lesions in #Patients with known or suspected lung cancer.
Drug was also approved in 2021 for identifying #OvarianCancer lesions.
fda.gov/drugs/news-eve…
#PCCR 's Phil Low has made significant discoveries in cancer treatment and therapy, most recently with FDA-approved Cytalux. Help fuel the #NextGiantLeap in cancer research by contributing today for #PurdueDayofGiving : purdue.university/37HMzBC
Are you heading to Toronto for the AATS 2024 Annual Meeting? Visit us at booth #1015 to learn more about the 1788 Platform and CYTALUX, SternalPlate and rigid fixation for sternal closure.
#1788Platform #ThoracicSurgery #SurgicalVisualization #CYTALUX #SternalPlate #AATS2024
#ICYMI : New injectable imaging diagnostic #Cytalux , which binds to cancerous tissue & glows for use in precision #lungcancer surgery, receives approval from U.S. FDA ft. Sunil Singhal (@PennSurgery/ Center for Surgical Health) On Target Laboratories, Inc. bit.ly/3YE6RSb
The FDA approves CYTALUX (pafolacianine) for the intraoperative identification of malignant lesions in Ovarian Cancer. On Target Laboratories, Inc. #SurgicalOncology #biotech #biotwitter fda.gov/news-events/pr…
Purdue Science American Lung Association Purdue Institute for Cancer Research Congrats, Dr. Low. An amazing feat to also make the American Cancer Society recommendations with #Cytalux .
Congratulations to Purdue Science professor Philip Low!
If you’d like to learn more about the FDA-approved CYTALUX, check out our #ThisIsPurdue podcast: purdue.university/3JenRbp
The FDA has approved an imaging drug known as Cytalux (pafolacianine), which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light. medicalxpress.com/news/2021-11-f… via Medical Xpress
medicalxpress.com/news/2022-05-r…
Study reveals #imaging approach with potential to detect lung #cancer earlier, at the #cellular level. #AbramsonCancerCenter
#Penn #NIR #nCLE #GregoryTKennedy #SunilSinghal #CDC #Cytalux #Cellvizio
We’re proud to announce that the Penn Medicine - Abramson Cancer Center clinical trial of CYTALUX, a drug that is administered before surgery for #ovariancancer patients that helps identify deadly ovarian tumors that may otherwise go undetected, has been approved by the U.S. FDA: spr.ly/6011JWwO9.
Is #SpyPhi by Stryker Endoscopy able to see #fluorescence from #Cytalux (@OnTargetLabs)? ISFGS #FGS Karol Polom Fernando Dip #ICG eLight